Payment overview · 2025
General Payments
$400.64
19 reported records · 6 companies
Healthcare provider profile · identity verified
William B Townsend, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROSEBURG, OR · NPI 1619959061
Verified facts
What the public records show
CMS Open Payments records show William B Townsend, MD received $400.64 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $236.90 | 59.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.52 | 14.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.88 | 8.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.04 | 8.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.80 | 4.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.50 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $368.66 | 17 |
| Education | $31.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.25 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.84 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.88 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 540 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 110 |
| Omeprazole | Omeprazole | 408 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 63 |
| Potassium Chloride | Potassium Chloride | 223 | 69 |
| Gabapentin | Gabapentin | 218 | 57 |
| Spironolactone | Spironolactone | 193 | 54 |
| Eliquis | Apixaban | 190 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 52 |
| Furosemide | Furosemide | 185 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 35 |
| Lisinopril | Lisinopril | 159 | 46 |
| Alprazolam | Alprazolam | 151 | 37 |
| Ezetimibe | Ezetimibe | 151 | 44 |
| Sertraline Hcl | Sertraline Hcl | 144 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 40 |
| Irbesartan | Irbesartan | 135 | 35 |
| Xarelto | Rivaroxaban | 126 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 52 |
| Montelukast Sodium | Montelukast Sodium | 121 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 115 | 25 |
| Metformin Hcl Er | Metformin Hcl | 112 | 32 |
| Trulicity | Dulaglutide | 110 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 35 |
| Prednisone | Prednisone | 104 | 49 |
| Felodipine Er | Felodipine | 102 | 28 |
| Trazodone Hcl | Trazodone Hcl | 102 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 31 |
| Simvastatin | Simvastatin | 94 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Ozempic | Semaglutide | 82 | 12 |
| Donepezil Hcl | Donepezil Hcl | 79 | 25 |
| Lorazepam | Lorazepam | 71 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Allopurinol | Allopurinol | 69 | 18 |
| Synthroid | Levothyroxine Sodium | 67 | 14 |
| Clonidine Hcl | Clonidine Hcl | 62 | 18 |
| Glimepiride | Glimepiride | 62 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 14 |
| Metformin Hcl | Metformin Hcl | 60 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 14 |
| Azithromycin | Azithromycin | 54 | 36 |
| Bupropion Xl | Bupropion Hcl | 53 | 13 |
| Carvedilol | Carvedilol | 52 | 11 |
| Lovastatin | Lovastatin | 48 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | 15 |
| Atenolol | Atenolol | 47 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 15 |
| Cephalexin | Cephalexin | 43 | 13 |
| Meloxicam | Meloxicam | 42 | 19 |
| Nifedipine Er | Nifedipine | 42 | 11 |
| Valsartan | Valsartan | 40 | 12 |
| Galantamine Er | Galantamine Hbr | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Famotidine | Famotidine | 38 | 14 |
| Fosinopril Sodium | Fosinopril Sodium | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 20 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Livalo | Pitavastatin Calcium | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Naproxen | Naproxen | 28 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Captopril | Captopril | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.64 · 19 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error